Travere Therapeutics (TVTX) Other Working Capital Changes (2021 - 2025)

Travere Therapeutics (TVTX) has 5 years of Other Working Capital Changes data on file, last reported at -$1.5 million in Q2 2025.

• Quarterly Other Working Capital Changes rose 30.88% year-over-year to -$1.5 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (up 75.33% YoY) and the FY2025 annual result came in at -$2.8 million, up 53.97% from the prior year.
• Other Working Capital Changes fell to -$1.5 million in Q2 2025, from -$1.3 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $6.4 million in Q1 2026 to a low of -$3.1 million in Q2 2023.
• A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes sank 117.54% — and 2024, when it soared 89.98%.
• Tracing TVTX's Other Working Capital Changes over 5 years: stood at -$1.9 million in 2021, then tumbled by 117.54% to -$4.0 million in 2022, then tumbled by 38.4% to -$5.6 million in 2023, then soared by 89.98% to -$559000.0 in 2024, then plunged by 162.25% to -$1.5 million in 2025.
• The last three Other Working Capital Changes figures came in at -$1.5 million (Q2 2025), -$1.3 million (Q1 2025), and -$559000.0 (Q4 2024), per Business Quant data.